Abstract Number: 1568 • ACR Convergence 2021
AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment
Background/Purpose: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout.…Abstract Number: L16 • 2019 ACR/ARP Annual Meeting
GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study
Background/Purpose: Giant cell arteritis (GCA) is the most common cause of primary vasculitis in adults. Corticosteroids are the cornerstone of the treatment. However, approximately 50%…Abstract Number: 2175 • 2019 ACR/ARP Annual Meeting
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of the Anti-ADAMTS-5 Nanobody®, M6495, in Healthy Male Subjects: A Phase I, Placebo-Controlled, First-in-Human Study
Background/Purpose: Osteoarthritis (OA) is a serious disease characterized by progressive joint failure and cartilage degeneration. In OA, ADAMTS-5 protease is upregulated, resulting in enhanced cleavage…Abstract Number: 2415 • 2019 ACR/ARP Annual Meeting
Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren ’s Syndrome (pSS) and RA Patients
Background/Purpose: Abatacept (ABA) has proven efficacy in autoimmune diseases and is being evaluated in pSS. The purpose of this investigation was to evaluate the pharmacokinetics…Abstract Number: 2536 • 2019 ACR/ARP Annual Meeting
Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States
Background/Purpose: Therapeutic drug monitoring of whole blood Hydroxychloroquine (HCQ) can help identify patients at risk of flares due to underexposure (e.g. severe non-adherence, < 200…Abstract Number: 2563 • 2019 ACR/ARP Annual Meeting
PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease
Background/Purpose: Anifrolumab, a fully human anti–IFN Type I receptor mAb, is under investigation for the treatment of SLE at a dose of 300 mg intravenously…Abstract Number: 530 • 2019 ACR/ARP Annual Meeting
Phase I Evaluation of the PDE4 Inhibitor LY2775240: Head to Head Comparison with Apremilast Using an Ex Vivo Pharmacodynamic Assay
Background/Purpose: LY2775240 is a potent and selective phosphodiesterase (PDE4) inhibitor being investigated as a potential treatment for inflammatory disorders, such as psoriasis. PDE4 is expressed…Abstract Number: 1398 • 2019 ACR/ARP Annual Meeting
Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: The in vitro binding affinity of sarilumab (KD 61.9 pM) for the human interleukin-6 receptor (IL-6R) is 15–22-fold higher than that of tocilizumab. This…Abstract Number: 1728 • 2018 ACR/ARHP Annual Meeting
Pharmacokinetics of Cyclophosphamide in Scleroderma Treated By Cyclophosphamide Versus Transplantation
Background/Purpose: The pharmacokinetics (PK) of cyclophosphamide (CP) and its primary active metabolite, 4-hydroxycyclophosphamide (4-OH-CP) have not been adequately studied in scleroderma. The hypothesis of this…Abstract Number: 1922 • 2018 ACR/ARHP Annual Meeting
Characterization of the Pharmacology and Pharmacokinetics of Cntx-4975, a High-Purity, Synthetic Trans-Capsaicin in Clinical Development for the Treatment of Moderate to Severe OA Knee Pain
Background/Purpose: CNTX-4975, a highly purified, synthetic trans-capsaicin and long-acting, non-opioid analgesic in phase 3 trials for moderate to severe OA knee pain, has demonstrated safety…Abstract Number: 2525 • 2018 ACR/ARHP Annual Meeting
Correlation Analysis between Sirukumab Exposure and Selected Safety Events Following Subcutaneous Administration Using Pooled Phase 3 Data in Rheumatoid Arthritis
Background/Purpose: To characterize the exposure-response (ER) relationship between systemic exposure to sirukumab (an anti- interleukin-6 [IL-6] human monoclonal antibody) and the occurrence of selected safety…Abstract Number: 2642 • 2018 ACR/ARHP Annual Meeting
Atacicept Dose Rationale for a Phase 3 Study in Patients with High Disease Activity and Auto-Antibody Positive SLE
Background/Purpose: Atacicept targets the B-cell-stimulators BLyS and APRIL, and is in development for the treatment of patients (pts) with SLE. Here, we integrated non-clinical and…Abstract Number: 1752 • 2017 ACR/ARHP Annual Meeting
Pharmacokinetics of Rituximab and Clinical Outcomes in Patients with ANCA-Associated Vasculitis
Background/Purpose: Response to rituximab (RTX) is variable in patients with ANCA-associated vasculitis (AAV), and predictors of treatment efficacy/relapse risk would be useful. Previous studies have…Abstract Number: 1809 • 2017 ACR/ARHP Annual Meeting
Lack of Placental Transfer of Certolizumab Pegol during Pregnancy: Results from a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study
Background/Purpose: There is a need for effective and safe treatment during pregnancy in women affected by chronic active inflammatory diseases such as rheumatoid arthritis. Adequate…Abstract Number: 192 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic and Pharmacokinetic Study of Verinurad in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment: A Phase 1, Open-Label Study
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1, single-dose, open-label study…